EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Evaluating the Effects of Silymarin on Expressing SBDSP1 and CASC11 Genes in HCT116 Colon Cancer Cells

Masoumeh Heshmati, Nazila Hasani-Reza Abad, Sanaz Pashapour

Journal of Kermanshah University of Medical Sciences · 2022

DOI: 10.5812/jkums-122802 ↗
AbstractBibliografische Angaben

Abstract

Background: Numerous studies have proven that silymarin can fight cancer, but the results remain controversial. Objectives: This study aimed to determine the expression levels of SBDSP1 and CASC11 genes in HCT116 colon cancer cells to evaluate the cytotoxic effects of silymarin. Methods: This study was conducted on HCT 116 cell lines, which were divided into groups treated with 6.25, 12.5, 25, 50, 100, 250, and 500 μg/mL silymarin and control group. The silymarin cytotoxicity was checked using the MTT assay, and the apoptosis induction rate was determined using the annexin (An)-V/PI kit and flow cytometry. The real-time PCR was also used to examine the expression of the CASC11 and SBDSP1 genes. The data were compared using one-way analysis of variance between groups. Results: The cell survival was reduced based on concentration and time, and IC50 concentrations were observed in 30.94, 41.50, and 46.41 μg/mL at 24, 48, and 72 hours, respectively. In addition, the treatment with IC50 concentration significantly increased in apoptosis after 48 hours compared to the control. A decrease in expression of CASC11 and SBDSP1 genes was observed in HCT116 cells treated with IC50 concentrations after 24 and 48 hours. Conclusions: According to the results, silymarin, as an active substance, declines survival, induces apoptosis, and reduces the expression of SBDSP1 and CASC11 genes on the HCT-116 colon cancer cell line based on concentration and time.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →